Dose-intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4d- breast cancer: Toxicity, clinical and pathological remission

Zentralblatt fur Gynakologie

Volumn 121, Issue 11, 1999, Pages 522-525

  Blohmer, J U ^a,b   Paepke, St ^a   Kissner, L ^a   Elling, D ^a   Fleige, B ^a   Grineisen, Y ^a   Lichtenegger, W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CARL THIEM KLINIKUM   (Germany)

Author keywords

Breast cancer; C erbB2; Estrogen receptor; p53; Preoperative chemotherapy

Indexed keywords

EPIRUBICIN; ESTROGEN RECEPTOR; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IFOSFAMIDE; MESNA; PACLITAXEL; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MASTECTOMY; NAUSEA; NEUROTOXICITY; ONCOGENE C ERB; PREOPERATIVE CARE; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FILGRASTIM; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MESNA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS; PROTECTIVE AGENTS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0032702124     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bauer KA: Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemostas 74 (1995) 94-100
2. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP: Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemostas 74 (1995) 449-453
3. Dahlbäck B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 85 (1995) 607-614
4. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90 (1993) 1004-1008
5. Daly E, Vessey MP, Hawkins MM, Carson JL, Cough P, Marsh S: Risk of venous thromboembolism in users of hormon replacement therapy. Lancet 346 (1996) 977-980
6. De Maat MPM, Kluft C, Jespersen J, Gram J: World distribution of factor V Leiden mutation. Lancet 347 (1996) 58
7. Herrmann FH, Koeling M, Schröder W et al.: Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol (in press) 1997
8. Leroy-Mattheron C, Levent M, Pignon J-M, Mendonca C, Gouault-Heilmann M: The 1691 G-A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemostas 75 (1996) 4-10
9. Ozawa T, Niiya K, Sakuragawa N: Absence of factor V Leiden in the Japanese. Thromb Haemostas 81 (1996) 585-596
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High-risk of thrombosis in patients homozygous for factor V Leiden (APC-resistance). Blood 85 (1995) 1504-1508
11. Schramm W, Dick A, Spannagl M et al.: Bavarian study on clinical relevance of thrombolic risk factors in women taking oral contraceptives. Ann Haematol 74 (1997) A108
12. Spannagl M, Dick A., Schramm W: Resistenz gegen aktiviertes Protein C bei Faktor V Leiden Mutation - Die häufigste angeborene Thromboseneigung in der gynäkologischen Praxis, gynäkologie + geburtshilfe hautnah 1 (1998) 7-14
13. Svensson PJ,Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330 (1994) 517-522
14. Toglia MR, Weg JG: Venous thromboembolism during pregnancy. N Engl J Med 335 (1996) 108-111
15. Vandenbroucken JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FRT: Increased risk of venous throm-bosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
16. Vandenbroucke JP, Van der Meer FJM, Heimerhorst FM, Rosendaal FR: Factor V Leiden: should we screen oral contraceptive users and pregnant women . Br Med J 313 (1996) 1127-1130
17. Witt I: APC-Resistenz (Faktor-V-Mutation). Klinische Bedeutung, Pathophysiologie und Diagnostik. Dt arztebl 95 (1998) A-2316-2323